...
首页> 外文期刊>Cellular immunology >Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients
【24h】

Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients

机译:西罗莫司与他克莫司治疗对同种异体肾移植受者的免疫调节作用

获取原文
获取原文并翻译 | 示例
           

摘要

The difference in immunoregulatory effects between sirolimus and tacrolimus on kidney transplantation remains unclear. In this study, a total of 18 living-donor-related kidney transplant recipients received sirolimus (n = 8) or tacrolimus (n = 10) treatment. Kidney function, acute rejection, peripheral blood CD4(+)CD25(+)FOXP3(+) regulatory T cells (Tregs), CD19(+)CD5(+)CD1d(+) regulatory B cells (Bregs), and panel reactivity antibody were analyzed after one and three years. Th1/2 cell polarization was also determined at one year. The proportion of Tregs in the recipients receiving tacrolimus significantly decreased to 3.69% and 2.49% at one and three years, respectively, compared to 6.59% in controls, whereas the proportion in the recipients receiving sirolimus remained at 6.67% and 5.66%, respectively. However, no differences in kidney function, acute rejection, proportion of Bregs, panel reactivity antibody, or the frequencies of Th1/2 cells were identified. In conclusion, unlike tacrolimus, sirolimus maintains the proportion of Tregs in kidney transplant recipients. (C) 2015 Elsevier Inc. All rights reserved.
机译:西罗莫司和他克莫司对肾脏移植的免疫调节作用的差异尚不清楚。在这项研究中,共有18位与活体供体相关的肾脏移植受者接受了西罗莫司(n = 8)或他克莫司(n = 10)的治疗。肾脏功能,急性排斥反应,外周血CD4(+)CD25(+)FOXP3(+)调节性T细胞(Tregs),CD19(+)CD5(+)CD1d(+)调节性B细胞(Bregs)和面板反应性抗体经过一年和三年的分析。 Th1 / 2细胞极化也确定在一年。在接受他克莫司治疗的受试者中,Tregs的比例在一年和三年时分别显着下降至3.69%和2.49%,而对照组为6.59%,而接受西罗莫司的受试者的比例分别保持在6.67%和5.66%。但是,没有发现肾脏功能,急性排斥反应,Bregs比例,面板反应性抗体或Th1 / 2细胞频率的差异。总之,与他克莫司不同,西罗莫司在肾脏移植受者中维持Treg的比例。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号